12 Best Multibagger Stocks to Buy Heading into 2026

7. Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Market Cap: $548.75 Million

Price Return over 1-Year: 224.47%

Upside Potential: 82.10%

Number of Hedge Fund Holders: 34

With strong 1-year returns and upside potential, Ventyx Biosciences, Inc. (NASDAQ:VTYX) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

As of December 18, 2025, 90% of analysts are bullish on Ventyx Biosciences, Inc. (NASDAQ:VTYX), setting a median price target of $14.00. This translates into a massive upside potential of 82.05%.

Amid this bullish momentum, Ventyx Biosciences, Inc. (NASDAQ:VTYX) was seen advancing its clinical and strategic initiatives, visible through the updates the company shared earlier in December.

On December 2, 2025, Ventyx Biosciences, Inc. (NASDAQ:VTYX) announced the addition of two prominent experts: Mark McKenna as Strategic Advisor and Dr. Peter Libby as Clinical Advisor. With these additions, the company strengthened its advisory board.

At the same time, Ventyx Biosciences, Inc. (NASDAQ:VTYX) shared progress in its ongoing phase 2 study of VTX2735 in patients with recurrent pericarditis. Management stated that this expanded advisory team will enable key decisions across both VTX2735 and VTX3232, the latter having already generated two positive Phase 2 data sets earlier this year.

Within the same announcement, Ventyx Biosciences, Inc. (NASDAQ:VTYX) also revised its guidance for the interim analysis of the Phase 2 recurrent pericarditis study. The revised guidance shifted the expected topline data release to Q1 2026. Management clarified that the modest delay enables the introduction of dose-ranging evaluations with a new once-daily formulation and expansion of clinical activity into Canada, the EU, and the UK. With this strategy, the company expects to help accelerate Phase 3 timelines. Meanwhile, the ongoing study’s focus on evaluating safety, pain reduction, and inflammatory markers remains robust, with extended follow-up planned for eligible patients.

That said, Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares declined 15.35% from the prior close of $9.38, ending the session at $7.94, with the stock falling 10% earlier in the day amid investor reaction to the delayed interim data.

Ventyx Biosciences, Inc. (NASDAQ:VTYX), a clinical-stage biopharmaceutical company, develops oral small-molecule therapies for autoimmune, inflammatory, and neurodegenerative diseases, with multiple Phase 2 programs targeting NLRP3, TYK2, and S1P pathways.